The sequencing of the human genome is likely to speed the discovery of factors involved in cancer pathogenesis and lead to an age of individually tailored anti-cancer drugs. But does the ability to obtain an abundance of genetic information mean that we necessarily know how to use it?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network
Scientific Reports Open Access 23 August 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
Cringely, R.X. The five rules of prognostication. Forbes ASAP (November 30, 1998).
The International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928–933 (2001).
Yu, A. et al. Comparison of human genetic and sequence-based physical maps. Nature 409, 951–953 (2001).
Collins, F.S. Shattuck lecture—medical and societal consequences of the human genome project. N. Engl. J. Med. 341, 28–37 (1999).
Shields, P.G. & Harris, C.C. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol. 18, 2309–2316 (2000).
Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–91 (1999).
The BAC Resource Consortium. Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature 409, 953–958 (2001).
Futreal, P.A. et al. Cancer and genomics. Nature 409, 850–852 (2001).
Rowley, J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243, 290–293 (1973).
Druker, B.J. & Lydon, N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3–7 (2000).
Elion, G.B. The purine path to chemotherapy. Science 24, 441–447 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratain, M., Relling, M. Gazing into a crystal ball–cancer therapy in the post-genomic era. Nat Med 7, 283–285 (2001). https://doi.org/10.1038/85414
Issue Date:
DOI: https://doi.org/10.1038/85414
This article is cited by
-
The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network
Scientific Reports (2018)
-
Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action
Fungal Diversity (2012)
-
Pharmacokinetic variability of anticancer agents
Nature Reviews Cancer (2005)
-
Pharmacogenomics: road to anticancer therapeutics nirvana?
Oncogene (2003)
